The Baltimore Biologics Drug Substance facility will serve customers across human and animal health market segments.

The transaction provides Curia with incremental capital and extends the maturities of its secured credit facilities.

In the evolving landscape of pharmaceutical production, fill-finish contract manufacturing has become a crucial area of focus ...

In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

The following offers perspectives from CDMOs and CROs on today’s oral solid dosage trends across drug development, ...

BioPlan Associates presents research and projections on the pharma sterile fill-finish industry’s future over the next 10 ...

Exploring Regulatory Affairs, the discipline dedicated to ensuring that new drugs and biologics are safe, effective, and ...

Significant growth in demand for pharmaceuticals, such as GLP-1s, increased R&D spending for autonomous manufacturing, and ...

The Noramco Group is investing $25M into its Halo Pharma facility in Whippany, NJ to establish sterile injectable ...

Aragen, a global Contract Research, Development and Manufacturing Organization (CRDMO), has made two senior level ...

Azelis, a service provider in the specialty chemicals and food ingredients industry, has been appointed exclusive distributor ...

The FDA has approved Celltrion’s OMLYCLO (omalizumab-igec) as the first and only biosimilar designated as interchangeable ...